1.70
+0.07(+4.29%)
Currency In USD
| Previous Close | 1.63 |
| Open | 1.58 |
| Day High | 1.74 |
| Day Low | 1.58 |
| 52-Week High | 8 |
| 52-Week Low | 1.05 |
| Volume | 1.52M |
| Average Volume | 1.6M |
| Market Cap | 53.64M |
| PE | -0.8 |
| EPS | -2.12 |
| Moving Average 50 Days | 2.3 |
| Moving Average 200 Days | 1.68 |
| Change | 0.07 |
If you invested $1000 in Acrivon Therapeutics, Inc. Common Stock (ACRV) since IPO date, it would be worth $102.16 as of January 14, 2026 at a share price of $1.7. Whereas If you bought $1000 worth of Acrivon Therapeutics, Inc. Common Stock (ACRV) shares 3 years ago, it would be worth $135.89 as of January 14, 2026 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 p
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
GlobeNewswire Inc.
Dec 17, 2025 2:34 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gen
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
GlobeNewswire Inc.
Dec 17, 2025 12:30 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gener